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e ability to track the biodistribution and fate of multiple cell populations administered to rodents has the potential to facilitate
the understanding of biological processes in a range of elds including regenerative medicine, oncology, and host/pathogen
interactions. Bioluminescence imaging is an important tool for achieving this goal, but current protocols rely on systems that have
poor sensitivity or require spectral decomposition. Here, we show that a bioluminescence resonance energy transfer reporter
(BRET) based on NanoLuc and LSSmOrange in combination with rey luciferase enables the unambiguous discrimination of
two cell populations in vivo with high sensitivity. We insert each of these reporter genes into cells using lentiviral vectors and
demonstrate the ability to monitor the cells’ biodistribution under a wide range of administration conditions, including the
venous or arterial route, and in dierent tissues including the brain, liver, kidneys, and tumours. Our protocol allows for the
imaging of two cell populations in the same imaging session, facilitating the overlay of the signals and the identication of
anatomical positions where they colocalise. Finally, we provide a method for postmortem conrmation of the presence of each cell
population in excised organs.
1. Introduction
Monitoring the biodistribution and fate of cells that are
exogenously administered into a host is fundamental for
understanding processes in a wide range of biomedical
research areas.is includes, for example, understanding the
mechanisms of stem cell therapies [1], tumour biology and
therapeutic response [2], or host/pathogen interactions [3].
Bioluminescence imaging (BLI) has emerged as an invalu-
able tool which allows to address such questions in a lon-
gitudinal and noninvasive manner. Researchers are now able
to easily insert luciferase genes into the cells of interest,
administer them to animal models, and immediately identify
not only the organs that they populate but also their viability,
proliferation, and any changes in biodistribution that might
occur over time. When mammalian cells are considered, an
enzyme-substrate pair system is usually employed, where the
cells of interest are genetically modied to express an
enzyme that oxidises a consumable substrate. A product of
this reaction is light [4], which can then be captured by
a charge-coupled device camera. Of the available systems,
the most commonly used is the luciferase from rey
(Photinus pyralis) [4] in combination with the substrate
luciferin.
e complexity of biological processes, however, will
often require that more than one cell population is imaged at
the same time to fully address certain scientic questions. For
example, it is now recognised that the immune system might
play an important role in areas such as stem cell therapies [5]
and oncology [6]. In such situations, it might be desirable to
monitor not only the stem or cancer cells but also immune-
relevant cells such as macrophages or T-cells. Likewise, in-
teractions between host and pathogen would also be better
understood by imaging multiple cell populations. Further-
more, the means to monitor multiple cell populations in vivo
can also reduce animal use in research (3Rs principle), where
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cells preconditioned in diﬀerent ways could be coadminis-
tered to the same animal and monitored individually.
Attempts to develop systems to monitor more than one
cell population in the same animal have often focused on the
use of luciferases with diﬀerent light emission peaks. Dual
imaging with a red-shifted ﬁreﬂy luciferase mutant in com-
bination with click beetle luciferase has been reported [7] and
so has a combination of red and green luciferases from click
beetle [8]. 'e disadvantage of these approaches is that the
light emission spectra of two populations tend to partially
overlap, and both luciferases oxidise the same substrate,
meaning the light from the two cell populations is emitted at
the same time, requiring a spectral decomposition algorithm
to clearly identify the anatomical source of each cell pop-
ulation. Spectral unmixing can lead to ambiguities, particularly
when in vivo imaging is considered, where light attenuation by
tissues can signiﬁcantly aﬀect the spectral properties of lu-
ciferase (this is shown for ﬁreﬂy luciferase in Figure S1(a)).
A diﬀerent approach to imaging more than one cell
population is to use luciferases with diﬀerent substrates,
which allows the signal from each cell population to be
acquired in sequence, as opposed to simultaneously, thus
precluding the need for data acquisition with diﬀerent
emission ﬁlters and the postacquisition processing for
spectral decomposition. Marine organisms like Gaussia
princeps and Renilla reniformis use coelenterazine as the
substrate, but a diﬃculty associated with luciferases from
these organisms is that light emission peaks in the
blue/green region of the spectrum [4]. Light in this region is
strongly attenuated in vivo due to tissue absorption and
scattering and results in poor imaging sensitivity, although
in vivo imaging with those pairs has been reported [9, 10].
More recently, an enzyme called Nanoluc (NLuc), which is
a structurally optimised version of the luciferase from the
deep sea shrimp Oplophorus gracilirostris, has been de-
veloped and reported to have brightness superior to that of
ﬁreﬂy or renilla luciferases, but with peak emission at
460 nm (blue) [11], thus suﬀering from the same drawbacks
as other marine luciferases. Bioluminescence resonance
energy transfer (BRET), where the bioluminescence from
a luciferase is used to excite a ﬂuorescent protein, is
a natural eﬀect occurring in organisms such as the jellyﬁsh
Aequorea victoria and now used as a tool to study protein
interactions [12]. 'is principle has been used to build
NLuc constructs which are optimised for in vivo imaging by
fusing this luciferase with a ﬂuorescent protein (FP) with
a large stokes shift. In these, NLuc is an energy (light) donor
for the ﬂuorescent acceptor, which then emits light>600 nm, an eﬀect that is possible because of the overlap
between the light emission peak of NLuc and the absorption
peak of the FP. Two of these systems have been recently
reported, employing (i) a cyan-excitable, orange-red FP [13]
or (ii) a large stokes shift monomeric orange FP [14]
(LSSmOrange, spectra shown in Figure S1(b)) as the receptor.
Although the performance of the latter for cell tracking has
been evaluated in vivo [14], no attempts have yet beenmade to
combine either reporter with ﬁreﬂy luciferase in order to
establish protocols for the coimaging of multiple cell
populations.
Here, we propose to establish and validate the methods
for the use of the BRET reporter system LSSmOrange/NLuc
in combination with ﬁreﬂy luciferase for monitoring the
biodistribution and fate of multiple cell populations in vivo
and postmortem.
2. Materials and Methods
2.1. Construct Preparation, Cell Line Transduction, and In
Vitro Imaging. 'e plasmids pHIV-Luc-ZsGreen and
pRetroX-Tight-MCS_PGK-OgNLuc were gifts from Bryan
Welm and Antonio Amelio, respectively (Addgene plasmids
#39196, #70186). 'e pHIV plasmid is a lentiviral construct
for bicistronic expression of the codon-optimised ﬁreﬂy
luciferase (luc2) and ZsGreen (via an IRES link) under the
constitutive EF1α promoter. 'e pRetroX-Tight-
MCS_PGK-OgNLuc vector is gamma retroviral and con-
tains the LSSmO_NLuc construct under a PGK promoter.
To enable a consistent comparison between ﬁreﬂy luciferase
(FLuc) and LSSmO_NLuc, the latter was cloned into
a plasmid with the same backbone as pHIV-Luc-ZsGreen,
thus resulting in a lentiviral vector with expression of
LSSmO_NLuc downstream of EF1α promoter (pHI-
V_OgNLuc). Lentiviral particles were produced by
cotransfection of the transfer plasmids with a packaging
plasmid (psPAX 2, addgene #12260) and the envelope
plasmid (pMD.2G, Addgene #12259) in HEK 293T-cells,
followed by concentration by ultracentrifugation and ti-
tration via ﬂow cytometry using HEK cells and previously
described methods [15].
'e mouse mesenchymal stem/stromal cell (MSC) D1
line was obtained from the American Type Culture Col-
lection (CRL-12424), and RAW 264.7 mouse macrophages
were obtained from the European Collection of Authenti-
cated Cell Cultures (#91062702). MSC D1s were transduced
with the FLuc or LSSmO_NLuc lentiviral particles using
a multiplicity of infection (MOI) of ∼5 and polybrene
(8 µg/mL in culture medium) and then expanded. RAW cells
were transduced with FLuc particles without polybrene,
which is toxic to this line, and the positive cell fraction was
then sorted based on ZsGreen expression using an Aria
ﬂuorescence-activated cell sorter (BD Biosciences). In all
cases, cells were maintained in Dulbecco’s Modiﬁed Eagle’s
medium with 10% foetal calf serum at 37°C in a humidiﬁed
incubator with 5% CO2.
For in vitro imaging, cells were suspended in poly-
propylene tubes or plated at diﬀerent densities in black 96-
well plates and allowed to settle for 2–4 h. 'en, D-luciferin
(150 µg/mL) or furimazine (20 µg/mL), both from Promega,
were added to the tubes or wells immediately prior to im-
aging with an IVIS spectrum system (PerkinElmer). 'ese
are working concentrations for in vitro studies as suggested
by PerkinElmer for D-luciferin and Promega for furimazine.
All bioluminescence data have been normalised to the ac-
quisition conditions and are displayed in radiance (pho-
tons/s/cm2/str). To obtain the bioluminescence spectra of
the cells, data were acquired with each of the emission ﬁlters
available in the system (500 to 800 nm in 20 nm steps),
and the normalised signal was plotted as a function of
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wavelength. For quantiﬁcation of light output, ROIs were
drawn around each of the tubes/wells, and the ﬂux in
photons per second (p/s) was calculated using Living Image
(PerkinElmer). A background control consisting of medium
and substrate only was included in all in vitro experiments
and subtracted from the experimental values.
2.2. In Vivo Imaging. BALB/c mice were purchased from
Charles River and housed in individually ventilated cages
under a 12 h light/dark cycle, with ad libitum access to
standard food and water. All animal experiments were
performed under a license granted under the UK Animals
(Scientiﬁc Procedures) Act 1986 and were approved by the
University of Liverpool ethics committee. All procedures
(administration of cells/substrates and imaging) were car-
ried out under anaesthesia with isoﬂurane.
For administration into animals, cells were harvested,
counted, suspended in phosphate buﬀered saline (PBS), and
kept on ice until injection. Cells (MSCs or a combination of
MSCs and RAWs) were suspended in 100 µL for injection via
the tail vein or into the arterial system via the left cardiac
ventricle as previously described [16].
For imaging, furimazine was used at a dose of 250 µg/kg
body weight and luciferin at a dose of 150mg/kg body
weight. For the initial optimisation of the administration
route, mice received MSCs intravenously (IV) and were
then imaged on the same day immediately after admin-
istration of furimazine subcutaneously (SC), in-
traperitoneally (IP), or IV via a cannula. In all subsequent
experiments, the mice were cannulated, moved to the
imaging chamber, and then the substrates were adminis-
tered IV immediately prior to data acquisition. 'e total
ﬂux from mice was quantiﬁed in the same manner as
described above for in vitro imaging. Changes in signal
intensity over time were captured with sequential acqui-
sition of data with intervals of 1 or 2min.
For sequential data acquisition from mice that received
cells expressing both reporters, animals were moved to the
imaging chamber and injected with furimazine, luciferin, or
PBS at diﬀerent time points. For animal welfare reasons, we
aimed at keeping the injection volumes as low as possible
(i.e., a total administration volume ≤200 µL). To overlay the
images obtained with each of the reporters, the raw lumi-
nescence images are displayed with pseudocolours and
overlaid with the photograph using ImageJ.
3. Results
3.1. +e NLuc BRET Reporter is Eﬀective and Yields a Light
Output that Exceeds Fireﬂy Luciferase. MSC D1s were
transduced with a lentiviral vector for the overexpression of
FLuc or LSSmO_NLuc downstream of an EF1α promoter
(Figure 1(a)) using an MOI of ∼5. In both cases, over 90% of
the cells expressed luciferase when assessed via immuno-
ﬂuorescence microscopy (Figure S2).'e emission spectrum
of cells expressing FLuc consisted of a single peak centred at
∼605 nm (Figure 1(b)). MSCs expressing LSSmO_NLuc, on
the contrary, displayed two emission peaks, one at 500 nm,
which is likely to correspond to the shoulder of the NLuc
peak that is centred at 460 nm, and a second peak at ∼575 nm
which corresponds to the emission peak of LSSmO
(Figure 1(b)), conﬁrming the functionality of the BRET
insert. To compare the performance of each reporter at
conditions relevant for in vivo imaging, the light output of
the cells was measured with a 620 nm emission ﬁlter
(bandwidth 18.9 nm) to exclude any light that would nor-
mally be attenuated by tissues. 'is condition also excludes
any NLuc light that is not transferred to LSSmO. Cells
expressing either of the reporters presented signiﬁcant light
emission (Figure 1(c)), but the output of those expressing
LSSmO_NLuc was nearly 35-fold higher than that of cells
expressing FLuc (7088 vs. 209 p/s/cell), suggesting a signif-
icantly greater brightness for this reporter system
(Figure 1(d)). Without any emission ﬁlters, the measured
light output was 204043 p/s/cell for LSSmO_NLuc and 1508
p/s/cell for FLuc.
3.2. Route of FurimazineAdministration Impacts Speciﬁcity of
Bioluminescence Signal. To determine adequate routes of
administration for the NLuc substrate (furimazine), mice
received 106 MSCs expressing LSSmO_NLuc via the tail
vein. Previous data suggest that this route of adminis-
tration leads to the cells immediately lodging exclusively
in the lungs [16]. Administration of furimazine sub-
cutaneously (under the skin of the neck) resulted in
a strong signal in this area (Figure 2(a)), which was not
speciﬁc to the lungs, suggesting that the substrate did not
eﬃciently reach the circulation. It should be noted that
furimazine (and other coelenterazine analogues) gives
background signal because of light emission from
enzyme-independent oxidation (autoluminescence). 'is
is most likely the source of the signal we have observed
under this condition. When administered IP, we detected
a weak but speciﬁc signal originating from the lungs
suggesting that some of the substrate was absorbed and
reached this organ. However, nonspeciﬁc signal was also
observed in the peritoneum (Figure 2(a), red arrows),
indicating that signiﬁcant amounts of the substrate were
trapped in this region. 'e IV route was the only ad-
ministration route that yielded a strong, speciﬁc signal
originating only from the lungs. 'e substrate clearance,
as measured by imaging the mice for up to 50 minutes
post-administration of furimazine, was also distinct for
each of those routes. Whereas the luminescent signal
persisted for more than 30 minutes when the substrate was
given SC or IP, the signal cleared very quickly after IV
administration, and was lost within 10 minutes of in-
jection (Figure 2(b)). 'is is in contrast to luciferin, which
has a longer half-life (Figure S3).
3.3. FLuc Signal In Vivo Is Stronger +an LSSmO_NLuc.
To assess whether the diﬀerences in signal intensity observed
in vitro are reﬂected in vivo, mice were injected with MSCs
expressing either of the reporters via the tail vein and imaged
for up to 3 days. For a direct comparison of light output,
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animals received the substrate IV irrespective of the reporter
system and were imaged immediately after administration
under identical acquisition conditions. 'e substrate was
administered via a cannula as the animal was in the imaging
chamber, enabling data acquisition to start within 5 seconds
of administration.
EF1α promoter Firefly luciferase IRES ZsGreen
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Figure 1: Bioluminescence of MSCs expressing a FLuc or an LSSmO_NLuc construct. (a) Arrangement of the lentiviral inserts used to
transduce the cells (not to scale). (b) Bioluminescence spectra of MSCs transduced with each of the constructs. (c) Bioluminescence imaging
of diﬀerent numbers of MSCs expressing LSSmO_NLuc (left) or FLuc (right). (d) Light output as a function of cell number. Error bars
denote SD from n � 3 experiments. Luciferin (150 µg/mL) was used as a substrate for FLuc and furimazine (20 µg/mL) as a substrate for
NLuc. An emission ﬁlter (620 nm) was applied.
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Figure 2: Impact of substrate administration route on signal speciﬁcity. MSCs (106) expressing LSSmO_NLuc were administered via the tail
vein and, on the same day, the mice were imaged using furimazine as a substrate. (a) Representative BLI of mice that received the substrate
SC, IP, or IV. 'ese cells are known to lodge in the lungs. Red arrows indicate areas with nonspeciﬁc signal. 'e signal obtained via each
route was probed with at least three individual animals. (b) Representative total ﬂux as a function of time as measured from the whole animal
(one acquisition every 2 minutes).
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For both systems, an intense, speciﬁc signal originating
from the lungs was seen on the administration day (d0)
which gradually decreased on the subsequent days sug-
gesting cell death (Figures 3(a) and 3(b)). 'e images for
all time points are displayed in the same colour scale to
allow a direct comparison of the signal changes over time,
but it should be noted that some signal was still present in
the lungs by day 3 (shown in Figure S4). Interestingly, the
signal intensity observed for the LSSmO_NLuc construct
was not stronger than that of FLuc, and in fact, it was
weaker on days 0 and 1. 'is is reﬂected in the quantiﬁ-
cation of the total ﬂux (Figure 3(c)), where the mean FLuc
signal was 15-fold stronger than LSSmO_NLuc on the
administration day (d0), 2.5-fold stronger on day 1, and
not diﬀerent or weaker than LSSmO_NLuc on days 2 and
3.
3.4. Fast Furimazine Clearance Enables Tracking of Two
Diﬀerent Cell Populations Individually under the Same Im-
aging Session. Having validated the sensitivity of both re-
porters, we sought to evaluate whether it is possible to track
two distinct cell populations independently. For this pur-
pose, we chose to coinject MSCs expressing LSSmO_NLuc
and RAW macrophages expressing FLuc. We injected both
cell types simultaneously via the left cardiac ventricle (106
each) as our previous studies have shown that this is the
most eﬃcient way to achieve a whole body distribution of
cells [16]. 'is approach enables cells to populate a variety of
organs, instead of being trapped in the lungs.
We explored the very short half-life of furimazine for
coimaging the two diﬀerent cell types. Because the signal is
cleared so quickly, it is possible to image both populations in
the same session as long as the signal from furimazine
expressing cells is acquired ﬁrst. We established an imaging
protocol that consisted of (1) tail vein cannulation, (2) ad-
ministration of furimazine IV and immediate data acquisition
to obtain the LSSmO_NLuc signal, (3) a waiting period of
15–20minutes to allow furimazine to clear, where the cannula
is ﬂushed to wash away any remaining furimazine, and (4)
administration of luciferin IV and immediate data acquisition
to obtain the FLuc signal.
'e BLI signal of MSCs and RAWs revealed whole body
distribution of both cell types on the administration day,
with signal clearly originating from the brain, liver, lungs,
and kidney (Figures 4(a) and 4(b)). 'is distribution is in
agreement with cell administration for both cell types via
the arterial route. BLI on the following days demonstrated
this is followed by a period where almost no signal was
detected, and then, a fast increase in signal intensity,
suggesting proliferation of both cell types (Figures 4(a) and
4(b)). MSCs proliferated mainly close to the limbs, par-
ticularly the hindlimbs, whereas the RAWs proliferated in
the head and in the abdominal region. 'ese observations
are supported by quantiﬁcation of the mean total ﬂux from
a ROI covering the whole animal’s body (Figure 4(c)),
showing that the MSC signal only starts to increase 15 days
after administration, whereas the RAW signal increases
earlier, between days 2 and 15.
MRI analysis of the mice on day 24 revealed the presence
of tumours in the skeletal muscle, particularly in the hind
legs and spine, and also in or around the liver (Figure S5), in
good agreement with the anatomical sites where bio-
luminescence was observed. A chart displaying the typical
signal ﬂux from such experiments is shown in Figure 4(d).
'ere is a peak in signal intensity immediately after fur-
imazine administration, when the MSC data are acquired,
followed by quick decay in signal, until the syringe is ﬂushed
and a minimal increase is seen as a response to the substrate
left in the cannula. After a period of 15–20 minutes, the
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signal is completely cleared and luciferin is injected for
acquisition of the FLuc data.
Data acquisition in a single imaging session allowed us to
overlay the signal originating from each of the cell pop-
ulations. 'e signal from the MSCs and RAWs on day 0 or
24 is shown in pseudocolours, together with an overlay of the
images, in Figure 5 and corresponds to the same data as
shown in Figures 4(a) and 4(b). 'is approach demonstrates
that, on the administration day (d0), the signals from MSCs
and RAWs strongly colocalised throughout the whole body,
whereas on day 24, the cells were present and had pro-
liferated at diﬀerent anatomical sites.
3.5. Identiﬁcation of Distinct Cell Population Postmortem.
In order to establish a protocol to identify the two diﬀerent
cell populations postmortem, we selected the liver, the
spleen, and tumour-containing musculoskeletal tissue
from the mice on day 24 as exemplary organs where we
suspected the MSCs and/or RAWs had populated. We
opted for the development of a protocol with sequential
data acquisition, thus providing unambiguous signal data
from each of the reporters. In this case, however, the order
of the data acquisition is inverted and the FLuc signal is
acquired before LSSmO_NLuc to take advantage of the
longer luciferin half-life. First, the mice received a SC
injection of luciferin 10 minutes prior to cervical dislo-
cation. It is well known that this allows the substrate
to reach the circulation and all organs. 'en, after con-
ﬁrmation of death, the tissues were harvested, collected in
black weighing boats, and imaged with no ﬁlters applied.
'ese processes capture the total luminescence from tissues
that contain FLuc (RAW cells). Figure 6, Step 2 displays the
data obtained under these conditions, which revealed
signals in the form of foci in the livers, which is consistent
with the pattern seen via MRI. No RAW cells were present
in the spleen or in the musculoskeletal tissue samples.
Subsequently, a 500 nm (bandwidth 20.2 nm) ﬁlter is ap-
plied, which represents the shortest available wavelength in
the IVIS spectrum system. Applying this ﬁlter eliminates
any signal originating from FLuc (Figure 6, Step 3). Finally,
the containers with the tissues are ﬁlled with furimazine
(5 µg/mL in PBS), allowed to settle for 1–2 minutes and
then imaged as in the previous Step (500 nm ﬁlter and the
same exposure conditions). 'is enables the camera to
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capture any NLuc photons that are not transferred to
LSSmO and is thus speciﬁc to areas containing the MSCs.
Here, we observed that no signal originated from the livers
or spleen, but a strong, speciﬁc, signal originated from
musculoskeletal tissue samples containing tumours.
4. Discussion
We have aimed at establishing a bioluminescence imaging
strategy to unambiguously monitor the biodistribution of
two cell populations independently.We opted to utilise FLuc
expression in one of the cell populations, given its wide-
spread adoption, whereas for the second cell population, we
opted to use a BRET reporter that uses the substrate fur-
imazine. To allow direct comparison of these systems, we
used the same constitutive promoter and equivalent MOI so
that the gene expression levels of the two reporters in the
MSCs would be similar. When measured in a dish, cells
expressing LSSmO_NLuc displayed a much greater signal
than those expressing FLuc. Although the use of the same
promoter and MOI does not guarantee the same expression
levels, the diﬀerences observed are too great to be explained
only by diﬀerent levels of protein expression between the
cells. Given the well-documented brightness of NLuc, we
suggest that our results reﬂect the brightness of this lucif-
erase and an eﬃcient energy transfer to LSSmO.
When the two luciferase systems were compared in vivo,
however, the diﬀerence in brightness was not observed.
'is ﬁnding could be based on the poor bioavailability of
furimazine which, unlike luciferin, has poor water solu-
bility and is commercialised as a stock solution in ethanol.
In fact, we have noticed the formation of precipitates if
furimazine is diluted in PBS and kept on ice for long
periods (>30min). In the experiments reported here, the
substrate was always diluted just before administration to
prevent precipitation, as this maximises the signal output.
However, this step was not enough to ensure eﬃcient
delivery to the circulation when using the SC or IP routes. It
is interesting that the original research paper describing the
LSSmO_NLuc construct involves several experiments in
which furimazine is administered IP [14] without the
authors giving any indications of unspeciﬁc background.
However, the authors moved to IV injections towards the
end of the study, suggesting that they also saw advantages
using this route. An earlier study involving the imaging of
NLuc expressing cells also reported a signiﬁcant back-
ground signal when IP administering furimazine [17],
suggesting that this is a common issue. However, even
d2
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d0
Photo MSC RAW Merge
Figure 5: Identifying colocalisation of MSCs and RAWs in vivo. 'e bioluminescence signal from each of the exogenously administered cell
types is displayed in pseudocolours (green, MSCs; red, RAWs) and then overlaid with a photograph of the mouse. Whereas a strong co-
localisation of the cells is seen on day 0, resulting in a yellow colour when the channels are merged, the two diﬀerent populations had
proliferated at diﬀerent anatomical locations by day 24, with minimal co-localisation at this time point.
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though IV administration seems to be the only suitable
route for this substrate, its half-life is very short, indicating
poor bioavailability and suggesting the need for improved,
aqueous soluble substrates, if signal output with this re-
porter is to be maximised. Indeed, our kinetic measure-
ments suggest a half-life much shorter than 1 minute (the
temporal resolution used here). 'is probably impacts the
ﬂux measurement, as in our experiments we ﬁxed the
acquisition time to 45–50 s. Because substrate availability to
the enzyme is unlikely to be that long, shorter acquisition
times might lead to a higher ﬂux. Yet, even with these
shortcomings, the signal intensity was strong enough for
easy identiﬁcation of the cell’s anatomical location after IV
or IC administration, conﬁrming the suitability of both
reporter systems for tracking cell biodistribution. Impor-
tantly, LSSmO_NLuc was no less sensitive than FLuc to
detect the small number of cells that remained in the lungs
of mice 3 days after IV administration, a period after which
the majority of the administered cells have already died.
We have used the short half-life of furimazine to our
advantage, as it allowed us to establish a protocol for imaging
the two cell populations under the same data acquisition
session. One of the major advantages of this method is that
the animal is not moved between imaging of each reporter,
facilitating the overlaying of the data. We noticed that this is
further improved by gently taping the limbs of the animal to
the chamber, preventing any movement that might aﬀect the
quality of the data. Our imaging protocol provides clear,
unambiguous acquisition of the signals from each luciferase
individually, and the diﬀerent conditions used here (delivery
to the lungs, whole body delivery, and tumour formation in
diﬀerent organs) suggest that this protocol is robust enough
to allow imaging under a range of conditions and at diﬀerent
tissue depths with success. 'is method is also appealing for
facilities that have imaging systems without emission ﬁlters,
a requirement for methods that rely on spectral de-
composition. It should be noted that, although we have been
able to image cells delivered to the brain via the arterial
system, these cells are probably trapped in brain capillaries
and have not reached the parenchyma [16]. 'e imaging of
cells expressing LSSmO_NLuc in the parenchyma of a brain
with an intact blood-brain barrier (BBB) still requires
validation, as some substrates can have limited BBB
permeability.
When the long-term behaviour of MSCs and RAWs are
considered, both cell populations formed tumours, but in
diﬀerent organs and at diﬀerent rates. Our previous data
showed that these MSCs tend to die within the ﬁrst days of
administration but a small pool of cells survive and form
osteosarcomas [16]. 'is is likely a consequence of their
extensive expansion in vitro leading to malignant trans-
formation, a well-documented eﬀect [18]. 'e RAW mac-
rophages, on the contrary, are known to be tumourigenic
[19]. In our study, these cells underwent signiﬁcant cell death
in the ﬁrst days but formed tumours in the livers by the end
of the experimental period. 'us, while the longitudinal
behaviour of these two cell types was not unexpected, their
unique in vivo fates facilitated the validation of the eﬃcacy of
the reporter systems under diﬀerent conditions of cell
distribution and tumour formation.
Because spatial resolution of BLI is poor when compared
with other imaging modalities, it is often desirable to
conﬁrm the location of the cells of interest by imaging
organs ex vivo at the experimental endpoint. 'is is also the
case for situations where only small numbers of viable cells
are left in the tissues, preventing in vivo detection due to
poor sensitivity. 'us, we established a protocol with se-
quential data acquisition that involved the detection of FLuc
at 605 nm and the detection of LSSmO_NLuc at 500 nm
(note that the BRET reporter emits at both 460 nm and
570 nm as the energy transfer is not 100% eﬃcient). With
this method, we were able to unambiguously detect each of
the cell populations in diﬀerent organs. Although we were
imaging tumours that were large enough to be detected by
MRI, we anticipate that the sensitivity of this method would
permit visualisation of small numbers of cells, particularly
for the population expressing NLuc, as this luciferase yields
very strong signal intensities ex vivo, where there is less
tissue attenuation. We opted to leave the organs intact, but
mincing them in smaller parts is likely to further increase
detection sensitivity of NLuc, by enabling a more eﬃcient
penetration of the substrate into the tissues.
1. Administration of luciferin SC.
Wait 10 minutes, cull, extract organs. 
2. Acquire bioluminescence data with open ﬁlter.
FLuc signal is obtained.
3. Apply 500 nm ﬁlter and acquire data under the same
exposure conditions. FLuc signal is eliminated. 
4. Immerse organs in 5 µg/mL furimazine. Repeat
acquisition with 500 nm ﬁlter. NLuc signal is obtained.
Radiance (p/sec/cm2/sr)106 108
Liver
Spleen
MS-tissue
Figure 6: Identiﬁcation of each cell population in organs post-
mortem. 'e liver, the spleen, and tumour-containing musculo-
skeletal (MS) tissue samples were harvested from mice and imaged
with a protocol that allows the identiﬁcation of FLuc (shown in step
2) or LSSmO_NLuc cells (shown in step 4). Here, livers contained
foci of RAW cells expressing FLuc, the spleen contained no ex-
ogenously administered cells, and the tumour-containing mus-
culoskeletal tissue consisted of MSCs expressing LSSmO_NLuc.
'e radiance scale is the same for all images.
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Finally, it should be noted that the use of these two
luciferase systems could be further expanded for other
purposes. For instance, there is potential for tracking up to
three diﬀerent cell populations by combining with ﬁreﬂy
luciferases that have diﬀerent emission spectra, although this
would entail the drawbacks associated with spectral de-
composition. 'is could be justiﬁed depending on the ex-
perimental design and the research questions being
addressed. 'ere is also a drive for imaging gene expression
in vivo by using constructs where luciferase expression is
driven by promoter activity [20], enabling speciﬁc mile-
stones to be identiﬁed in situ such as the diﬀerentiation of
stem cells postadministration or the activation of metastatic
genes in cancers. In such cases, the combination of these
reporters in the same cell would enable a very sensitive
detection of gene expression (for example, using FLuc
downstream of speciﬁc promoters) and, at the same time, the
monitoring of cell proliferation and/or viability (using
LSSmO_NLuc downstream of a constitutive promoter).
5. Conclusions
Distinct cell populations expressing FLuc or the BRET re-
porter LSSmO_NLuc can be unambiguously discriminated
in vivo with similar sensitivities under a wide range of
conditions including cells distributed throughout the whole
body or in the form of tumours in speciﬁc organs. Although
the poor bioavailability of furimazine requires intravenous
administration of this substrate, its short half-life enables the
imaging of both populations in the same session, facilitating
image overlay and the identiﬁcation of areas of
colocalisation. With the application of light emission ﬁlters,
this imaging system allows the postmortem conﬁrmation of
tissues that have been populated by each cell fraction.
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